Name | Jolkinolide B |
Description | Jolkinolide B is a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud. Jolkinolide B induces apoptosis in cancer cells. Jolkinolide B can be used for studies on preventing and treating osteolysis. |
In vitro | Jolkinolide B has potent anti-inflammatory, and antitumor activities. Jolkinolide B is able to enhance apoptosis of human leukemic HL-60 and THP-1 cells, at least in part, through downregulation of JAK2/STAT3 and bcl-2, and upregulation of Bax and cytosolic cytochrome c. Jolkinolide B inhibited RANKL-induced osteoclast differentiation from bone marrow macrophages (BMMs) without cytotoxicity. Furthermore, the expression of osteoclastic marker genes, such as tartrate-resistant acid phosphatase (TRAP), cathepsin K (CtsK), and calcitonin receptor (CTR), was significantly inhibited. Jolkinolide Binhibited RANKL-induced activation of NF-κB by suppressing RANKL-mediated IκBα degradation. Moreover, Jolkinolide B inhibited RANKL-induced phosphorylation of mitogen-activated protein kinases (p38, JNK, and ERK)[1]. |
Storage | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 3.3 mg/mL (10 mM), Sonication is recommended.
|
Keywords | cancer | inhibit | human | Apoptosis | Jolkinolide B | U937 | Inhibitor | leukemic | cells |
Inhibitors Related | TBHQ | Myricetin | Diethylmaleate | Glucosamine | Lidocaine hydrochloride | Artemisinin | Apremilast | Dexamethasone | Indole-3-carbinol | Lenalidomide | Diallyl disulfide | 2,3-Butanediol |
Related Compound Libraries | Anti-Tumor Natural Product Library | Terpene Natural Product Library | Bioactive Compound Library | Pain-Related Compound Library | Selected Plant-Sourced Compound Library | Anti-Inflammatory Traditional Chinese Medicine Compound Library | Natural Product Library for HTS | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library |